Keyur Parekh

Novartis AG (NYSE: NVS) has been on a tear since hitting a year-over-year nadir in June. As the drugmaker rides positive partnerships, drug approvals and trial successes, one analyst is projecting good health in the near-term.  The Analyst  Goldman Sachs analyst Keyur Parekh...

AstraZeneca plc (ADR) (NYSE: AZN) announced that its anti-platelet drug, Brilinta, had failed to meet the primary end point in the EUCLID trial. Goldman Sachs’ Keyur Parekh maintained a Sell rating on the company, with a price target of 4,000p. Related Link: AstraZeneca's Brilinta...

Goldman Sachs maintains its Buy rating on Bayer AG (ADR) (OTC: BAYRY) following its $66 billion takeover of Monsanto Company (NYSE: MON) and said investors have now become more positive about the strategic fit and the resultant new entity. Bayer has agreed to buy Monsanto for $128 per share,...

Goldman Sachs’ Keyur Parekh believes the current stock valuation of Shire PLC (ADR) (NASDAQ: SHPG) is very attractive relative to the company’s growth profile and outlook for cash generation. Parekh re-initiated coverage of the company with a CL-Buy rating and price target of 6300p....

AstraZeneca plc (ADR) (NYSE: AZN) announced that the US FDA had issued a complete response letter, or CRL, for its hyperkalaemia asset ZS-9. Following a preapproval manufacturing inspection, the CRL raised concerns around the manufacturing process and product quality. Goldman Sachs’ Keyur...

GlaxoSmithKline plc (ADR) (NYSE: GSK) is near its 52-week lows after having fallen 6.2 percent this year. Following topline results from GlaxoSmithKline's SUMMIT study, Goldman Sach's Keyur Parekh called the results an "unexpected disappointment." For GSK financially, the results were only a "...